{
    "organizations": [],
    "uuid": "470ce8e2ffd20d7ab04804c438e4df0efabd4454",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-lillys-taltz-receives-us-fda-appro/brief-lillys-taltz-receives-u-s-fda-approval-for-label-update-to-include-data-for-psoriasis-involving-the-genital-area-idUSASC0A37S",
    "ord_in_thread": 0,
    "title": "BRIEF-Lilly's Taltz Receives U.S. FDA Approval For Label Update To Include Data For Psoriasis Involving The Genital Area",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 22 (Reuters) - Eli Lilly and Co:\n* LILLYâ€™S TALTZ (IXEKIZUMAB) RECEIVES THE FIRST U.S. FDA APPROVAL FOR LABEL UPDATE TO INCLUDE DATA FOR PSORIASIS INVOLVING THE GENITAL AREA\n* LABEL UPDATE IS EFFECTIVE IMMEDIATELY IN UNITED STATES Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-22T20:39:00.000+03:00",
    "crawled": "2018-05-23T15:22:09.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "eli",
        "lilly",
        "co",
        "lilly",
        "taltz",
        "ixekizumab",
        "receives",
        "first",
        "fda",
        "approval",
        "label",
        "update",
        "include",
        "data",
        "psoriasis",
        "involving",
        "genital",
        "area",
        "label",
        "update",
        "effective",
        "immediately",
        "united",
        "state",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}